Mechanism of Action:
- Modified fragment of human growth hormone (amino acids 177-191)
- Stimulates β-3 adrenergic receptors in adipocytes
- Activates hormone-sensitive lipase
- Accelerates fatty acid metabolism in mitochondria
- Suppresses de novo lipogenesis in liver
Recommended for:
- Patients with morbid obesity (BMI > 35)
- Individuals with metabolic syndrome and insulin resistance
- Ineffectiveness of traditional weight loss methods
- Athletes during cutting phase for maximum fat burning
- Patients with dyslipidemia and abdominal obesity
Research and Studies.
Clinical studies demonstrate:
- 2-3 kg weight loss per week with course application
- 25-30% reduction in visceral fat volume over 12 weeks
- Lipid profile improvement in 80% of patients with dyslipidemia
- 40-50% increase in insulin sensitivity
- Absence of hyperglycemic effects and influence on IGF-1
- Morbid obesity (BMI > 35)
- Metabolic syndrome with abdominal obesity
- Dyslipidemia and hypercholesterolemia
- Insulin resistance and prediabetes
- Complex therapy of hepatic steatosis
The drug is dissolved in 1-2 ml of sterile water for injections and administered subcutaneously in the abdominal area. Recommended dosage is 500-1000 mcg once daily, preferably in the morning on an empty stomach. Treatment course duration 12-16 weeks with possible repetition after 4-week break.
Contraindications:
- Pregnancy and lactation
- History of malignant neoplasms
- Severe hepatic and renal insufficiency
- Acute cardiovascular diseases
- Individual hypersensitivity to peptides
Side Effects:
- Hyperemia and pain at injection site
- Transient headache at course beginning
- Mild dyspeptic phenomena
- Allergic reactions in case of intolerance
- Increased appetite during first weeks of use
